Harmonizing Manufacturing across Multiple Sites and Regions

Size: px
Start display at page:

Download "Harmonizing Manufacturing across Multiple Sites and Regions"

Transcription

1 Harmonizing Manufacturing across Multiple Sites and Regions ISCT North America Regional Meeting Philadelphia, Pennsylvania Byron T. McAllister B.T. McALLISTER ASSOCIATES, INC. Tuesday, 10 September 2013

2 Harmonizing Manufacturing across Multiple Sites and Regions The Change Control Management Process (A Tutorial): An Essential Element for Successful Transition to Commercialization (Read: Product Approvals, Prescriptions Equal Positive Cash Flow) It must include: 1. Prospective written and approved change management plan; 2. Project management deliverables; and 3. Periodic effectiveness checks.

3 The Change Control Management Process Why You Need A Comprehensive Change Control Management Process To ensure that all changes to GMP and GMP-related activities are: Documented, Reviewed, Approved, Implemented, and Controlled

4 The Change Control Management Process There must be clear rules for: Proposing, Classifying, Reviewing, Approving, Implementing, Closing, Follow-up, and Reporting of Changes

5 The Change Control Management Process CCMP applies to: The management of changes to a GMP or GMP-related activity CCMP Does Not apply to: Unexpected / unplanned result or action (deviation) occurring during a GMP or GMP-related activity, which must be treated through the Deviation Management Process N.B.: Yes, the CCMP process may be invoked as part of the deliverables in terms of Corrective and / or Preventive Action(s) (CAPA) as the result of a material Deviation [legal definition], but this is a topic for another day Pre-scheduled calibration and preventative maintenance events.

6 The Change Control Management Process DEFINITIONS: A Change: Is any prospective addition, modification or deletion with respect to raw material, components, process, product, method, equipment (including computerized system), specification, responsibility and / or facility used to perform a GMP related activity

7 The Change Control Management Process GMP Related Activity Any activity/system which may potentially impact the equipment or system design and operation, validation status, process performance, safety or product quality attributes

8 The Change Control Management Process When Is GMP Compliance Expected / Required? The Process / Product Development Life Cycle EU versus U.S. FDA Controversy remains, but Flexibility in Design Decision-Making Is Paramount Patient Safety and First-in-Man considerations Validity of Tests Sterility, Apryrogenicity, Freedom from Other Adventitious Agents

9 The Change Control Management Process What Is A Locked Process? Processes Related To Patient Safety for Phase 1 Objectively, Processes Related To Manufacturing and Control for Phase 2 and beyond Certainly, for Phase 3 Pivotal Efficacy Trials Absolutely, for Product Consistency Batch Production Bio-Batches, Demonstration Batches, Process Validation Batches Pre-Approval Inspection (PAI) to Demonstrate Full GMP Compliance

10 The Change Control Management Process Examples of Different Types of Quality System Changes: Administrative Change: change to a document- format, spelling, typographical error correction, or clarification which does not include any change to the intent or meaning Emergency Change: change which must be implemented immediately due to an issue of safety or immediate product loss Local Change: a change in which the scope is limited to one site/facility only Permanent Change: change is not temporary in nature. Major Change: any change that impacts a regulatory filing or commitment (i.e., the Registered Details ) Minor Change: any change that does not impact regulatory filings Multisite Change: a change that impacts more than one site Temporary Change: any change of a specific duration or number of batches after which the initial conditions will be restored

11 Multi-Site Change Control Management Why Is Multi-Site Change Control Management So Complicated? Changes May Originate From Many Different Sources A Request for Change may be initiated by: 1. Sponsor 2. Supplier (manufacturer of the raw or starting material)* 3. Clinical site* 4. CMO, CRO or CTL* * Must be accepted and implemented by the Sponsor in any event

12 Multi-Site Change Control Management Drivers of Complexity: Never Be Single Sourced Golden Rule of Quality Assurance Catastrophe Backup Planning Additional Site(s) of Manufacture Manufacturing Formula Master Control One Product for Worldwide Market Raw Materials and Components Grades and Quality Specifications Products Requiring Manipulation at Clinical Administration Site Sponsor Must Supply Everything Needed for Consistency

13 Multi-Site Change Control Management Regulatory Categories: Classification of regulatory action required before a change can be made effective. Type A: Changes can be implemented immediately and need no notification of the Health Authorities Type B1: Changes can be implemented immediately, but require subsequent notification of the Health Authorities. Type B2: Changes can be implemented immediately AFTER notification of the Health Authorities. Type C: Changes require approval by Health Authorities PRIOR to implementation.

14 Multi-Site Change Control Management Process Elements for the CCMP: Request Must Have a Proponent Drives the entire process QA is only the information traffic controller, i.e., facilitator, communicator Implementation Planning Deliverables (a comprehensive Project Management list of all affected processes and products) Expected Timeline (Often a matter of hurry up and wait!) Actions to maintain quality and compliance to GMP Validation considerations Stability confirmation

15 Multi-Site Change Control Management Review of Multi-Site Changes: Requests Must Be Reviewed by the Respective Heads of QA and RA Assess the Impact On Each Site Data Requirements for Eventual Submission Approve or Deny the Change Request

16 Multi-Site Change Control Management Process Elements for the CCMP (Cont): Implementation of the Change Material Quarantined Until Changes Verified All Activities Completed All Deliverables Available and Approved Changes Made Effective Date of First Implementation Batch Number(s) Involved

17 Multi-Site Change Control Management Process Elements for the CCMP (Cont): Effectiveness Checks Audit, Audit, Audit! Corrective Action Where Necessary See the CAPA Process Close Out the Change Request Archive Update the Registered Details as appropriate See Ongoing Process / Product Monitoring Management Process

18 Multi-Site Change Control Management The Value Proposition: The Obvious: GMP Compliance, it s the Law! ICH Q10 requires it Departmental System Owner of the GMP System/Activity for technical approval of comprehensive implementation plan, identification of deliverables, revalidation requirements, if applicable, etc. Local/Site QA for accuracy, adequacy, completeness and compliance to Quality Policies, Standards and SOP s. If you are a CMO or CRO or CTL, customer approval of implementation plan, revalidation requirements, etc. (as required) Safety, Health & Environment (SHE) for compliance to applicable company and regulatory SHE requirements.

19 The Value Proposition (Con t): The Not So Obvious: Provides for a continuum of process and product development progress (Development History), and Provides for a link back to the original R&D Scientist(s)

20 And Finally...

21 QUESTIONS??

While the recognition

While the recognition Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change

More information

Packaging Operations Technical Subcommittee

Packaging Operations Technical Subcommittee Documentation About the Presenter John Derek Thompson Lead Sterile Engineer, DePuy Synthes Certified Professional with the IOPP Member of the Medical Device Technical Committee Chairman of the Member of

More information

CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)

CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions) 21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software

More information

MASTER VALIDATION PLAN PROCEDURE DRAFT DRAFT OF A POSSIBLE COMPUTER SYSTEMS VALIDATION MASTER PLAN PROCEDURE

MASTER VALIDATION PLAN PROCEDURE DRAFT DRAFT OF A POSSIBLE COMPUTER SYSTEMS VALIDATION MASTER PLAN PROCEDURE DRAFT OF A POSSIBLE COMPUTER SYSTEMS VALIDATION MASTER PLAN PROCEDURE 1. PURPOSE The purpose of this SOP is to define the minimum requirements for Computer Systems Validation (CSV) at (insert name of company

More information

Pharmaceutical quality requirements

Pharmaceutical quality requirements Pharmaceutical quality requirements through development to commercial medicinal product December 4, 2014 Karin Walhagen Biomedicine the Profession Biomedicine Master Program at Lund University Patient

More information

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC)

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC) Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls

More information

EU Annex 11 update. An ISPE interpretation

EU Annex 11 update. An ISPE interpretation EU Annex 11 update An ISPE interpretation ISPE Interpretation Published by Winnie Cappucci Chris Clark Tim Goossens Sion Wyn Disclaimer ISPE cannot ensure and does not warrant that computerized systems

More information

OECD and EPA GLP Differences

OECD and EPA GLP Differences OECD and EPA GLP Differences Annette Leslie RQAP-GLP Du Pont Pioneer Ankeny Iowa I conduct studies in the US, so Why do I care about oecd regulations? Disclaimer: I cannot cover all the differences in

More information

EU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011

EU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011 Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill

More information

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,

More information

Documenta tion and Records

Documenta tion and Records Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping

More information

Industry Perspective on Manufacturing in Early Development

Industry Perspective on Manufacturing in Early Development Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical

More information

CAPA Management: Best Practices and FDA QSR Mandate WHITE PAPER. ComplianceQuest In-Depth Analysis and Review

CAPA Management: Best Practices and FDA QSR Mandate WHITE PAPER. ComplianceQuest In-Depth Analysis and Review CAPA Management: Best Practices and FDA QSR Mandate WHITE PAPER ComplianceQuest In-Depth Analysis and Review CAPA Management: Best Practices and FDA QSR Mandate Establishing a corrective and preventive

More information

Data Integrity Why is it important? DADM Conference - 22 August 2017

Data Integrity Why is it important? DADM Conference - 22 August 2017 Data Integrity Why is it important? DADM Conference - 22 August 2017 Maibritt Haugaard Møller, System Validation Expert Mette Ravn, Vice President, Data Management, IT and System Validation Overview of

More information

Guidelines for Process Validation of Pharmaceutical Dosage Forms

Guidelines for Process Validation of Pharmaceutical Dosage Forms Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical

More information

Change Control Dealing with Changes in Investigational Medicinal Products

Change Control Dealing with Changes in Investigational Medicinal Products Change Control Dealing with Changes in Investigational Medicinal Products by Kerstin Kruithoff-Ley Changes accompany us throughout our lives. We have to be able to deal with them successfully and use them

More information

CMC Activities for Commercialization: PAI, QMS, and BLA/NDA. NEPDA Dinner Meeting Cambridge, MA 16 May 2018

CMC Activities for Commercialization: PAI, QMS, and BLA/NDA. NEPDA Dinner Meeting Cambridge, MA 16 May 2018 CMC Activities for Commercialization: PAI, QMS, and BLA/NDA Advancing from Clinical to Commercial The Commercialization Roadmap NEPDA Dinner Meeting Cambridge, MA 16 May 2018 Standards Certification Education

More information

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY  ISSN Review Article INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C

More information

Pharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit

Pharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit Pharmaceutical Good Manufacturing Practice Page 1 of 6 Why Attend A robust quality system that meets the requirements of pharmaceutical regulators is an essential element of every good pharmaceutical manufacturing

More information

EU Annex 11 US FDA , (g), (i), 11 Orlando López 09-APR

EU Annex 11 US FDA , (g), (i), 11 Orlando López 09-APR Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill

More information

Change Control Overview

Change Control Overview Change Control Overview Kelly Thomas Atlantic Technical and Validation Services Copyright 2014 by Atlantic Technical and Validation Services, LLC. 1 Session Outline Discuss Regulations Governing Change

More information

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Trinity College Dublin QP Forum 2017 Tuesday 25 th April Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current

More information

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation

More information

PACIFIC RIM CONSULTING COMMENTS ON FDA PROPOSAL TO REVISE GLPS

PACIFIC RIM CONSULTING COMMENTS ON FDA PROPOSAL TO REVISE GLPS PACIFIC RIM CONSULTING COMMENTS ON FDA PROPOSAL TO REVISE GLPS 1. GLP Quality System While many of the requirements of the existing regulation are consistent with a GLP quality system, FDA believes that

More information

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO 23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,

More information

DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS

DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS GLOBAL PROVIDER, LOCAL SOLUTIONS IN YOUR LANGUAGE DATA INTEGRITY ASSURANCE AS KEY FACTOR FOR SURVIVING CORPORATE AUDITS AND REGULATORY INSECTIONS Francesco Amorosi PhD Octorber 2017 DATA INTEGRITY & CSV:

More information

Good Distribution Practices Toolkit Change Control 10 March 2016

Good Distribution Practices Toolkit Change Control 10 March 2016 Good Distribution Practices Toolkit Change Control 10 March 2016 1 Disclaimer The content of this presentation were derived mainly from WHO training material on Change Control and edited to suit the Distributor

More information

Audit Program Background Definition Management Example Content Risk assessment approach

Audit Program Background Definition Management Example Content Risk assessment approach AUDIT PROGRAM Audit Program Background Definition Management Example Content System audits vs study audits Risk assessment approach ICH-GCP E6 new content Management Example 2 Background - Definition There

More information

CSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017

CSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017 CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection

More information

Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer

Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer Calyx Chemicals & Pharmaceuticals Ltd Unit:

More information

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER 7 2016 TUUSULA FINLAND Timo Kuosmanen STERIS Finn-Aqua Timo_Kuosmanen@steris.com AUDIT TRAIL IN CRITICAL UTILITIES MONITORING CURRENT TRENDS CONTENTS BACKGROUND

More information

AAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1

AAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1 AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences

More information

Strategies to Revise Quality Policy and Quality Objectives. Eileen Cortes February 22, 2017

Strategies to Revise Quality Policy and Quality Objectives. Eileen Cortes February 22, 2017 Strategies to Revise Quality Policy and Quality Objectives Eileen Cortes February 22, 2017 Agenda Elements of Compliance Quality Policy Outline Quality Strategy and Objectives Case Study Open Discussion

More information

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,

More information

Contact:: (609) Details please visit our website:

Contact:: (609) Details please visit our website: SunGen Pharma aims to create a healthier future for patients while increasing shareholder value through the development and introduction of quality, affordable generic products by experienced, passionate

More information

Overview of Regulatory Requirements for API and Formulations

Overview of Regulatory Requirements for API and Formulations Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed

More information

Outsourcing - managing risks and opportunities over which you now have less control

Outsourcing - managing risks and opportunities over which you now have less control Outsourcing - managing risks and opportunities over which you now have less control Kevin O Donnell, PhD PDA Meeting, Dublin 22 nd November 2018 Slide 2 Typical Examples The key GMP Requirements & Guidance

More information

Pharmaceutical Quality System (PQS)

Pharmaceutical Quality System (PQS) Implementation of ICH Q8, Q9, Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Structure of

More information

White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU

White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between

More information

Implement an Effective Change Management System throughout GMP and Validation Environments. Eileen Cortes February 23, 2017

Implement an Effective Change Management System throughout GMP and Validation Environments. Eileen Cortes February 23, 2017 Implement an Effective Change Management System throughout GMP and Validation Environments Eileen Cortes February 23, 2017 Agenda Change Management Principles Change Management Process and Change Control

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org February 22, 2011 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,

More information

Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document

Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions

More information

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines

More information

PART 58 GOOD LABORATORY PRACTICE FOR NONCLINICAL LABORATORY STUDIES

PART 58 GOOD LABORATORY PRACTICE FOR NONCLINICAL LABORATORY STUDIES Part 58-explanation of changes Scope ( 58.1) We propose to expand the scope of FDA-regulated nonclinical laboratory studies to specifically include toxicity studies. For purposes of this proposal, toxicity

More information

PART 58 GOOD LABORATORY PRACTICE FOR NONCLINICAL LABORATORY STUDIES

PART 58 GOOD LABORATORY PRACTICE FOR NONCLINICAL LABORATORY STUDIES Part 58-explanation of changes Scope ( 58.1) We propose to expand the scope of FDA-regulated nonclinical laboratory studies to specifically include toxicity studies. For purposes of this proposal, toxicity

More information

SITE MASTER FILE For MHRA

SITE MASTER FILE For MHRA ABC CO., LTD. For MHRA Prepared by Date Approved by Date Verified by Date Document No.: SMF, Version No: 01, Effective Date: 09/05/06 Document No.: SMF Version No.: 01 Effective Date: 09/05/06 Page 2 of

More information

Focused Trends from the FDA

Focused Trends from the FDA Focused Trends from the FDA GXP INSPECTION READINESS Jolly Bhatia Sr. Director, QA Alnylam September 21, 2017 Credits: Tim Maines, Arya Tavana, John French, Roan Martin 13% of FDA Complete Response Letters

More information

GUIDE TO INSPECTIONS OF QUALITY SYSTEMS

GUIDE TO INSPECTIONS OF QUALITY SYSTEMS FOOD AND DRUG ADMINISTRATION GUIDE TO INSPECTIONS OF QUALITY SYSTEMS 1 1 August 1999 2 Guide to Inspections of Quality Systems This document was developed by the Quality System Inspections Reengineering

More information

Developing a European First-in-Human Study: Three Key Decisions

Developing a European First-in-Human Study: Three Key Decisions Developing a European First-in-Human Study: Three Key Decisions By Nicole Feist, BA Clinical A key step in the translational medicine benchtop to bedside process model is the move from research and preclinical

More information

ICH Q8/Q8(R)

ICH Q8/Q8(R) Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since

More information

Regulatory Overview Annex 11 and Part 11. Sion Wyn Conformity +[44] (0)

Regulatory Overview Annex 11 and Part 11. Sion Wyn Conformity +[44] (0) Regulatory Overview Annex 11 and Part 11 Sion Wyn Conformity +[44] (0) 1492 642622 sion.wyn@conform-it.com 1 Two Key Regulations Annex 11 21 CFR Part 11 Apply to the regulated company, but often have a

More information

Introduction to 21 CFR 11 - Good Electronic Records Management

Introduction to 21 CFR 11 - Good Electronic Records Management INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY, BIOLOGY AND CHEMISTRY Review Article Introduction to 21 CFR 11 - Good Electronic Records Management Pal Tapas Kumar* and Maity Subhasis NSHM Knowledge Campus,

More information

GMP for ATMP should be a document annexed to standard GMP (a new Annex) and not a stand-alone document.

GMP for ATMP should be a document annexed to standard GMP (a new Annex) and not a stand-alone document. Leem comments on Commission proposal for Good Manufacturing Practice for Advanced Therapy Medicinal Products 1. General comments Line number(s) of the relevant text General comment

More information

GMP for ATMP. Advanced Therapy Medicinal Products Key2Compliance AB

GMP for ATMP. Advanced Therapy Medicinal Products Key2Compliance AB GMP for ATMP Advanced Therapy Medicinal Products 2018 Key2Compliance AB 1 Content Background and regualtory requirements GMP Walkthrough Quality Risk Management 2018 Key2Compliance AB 2 Background and

More information

Data Integrity: Production Environment

Data Integrity: Production Environment Data Integrity: Production Environment MANUAL AND AUTOMATED SYSTEMS Ciara Turley GMP Conference 12 th November 2014 Content GMP Guide requirements and application to processing equipment Security Audit

More information

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality

More information

CONTRACT RESEARCH SERVICES

CONTRACT RESEARCH SERVICES 1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply

More information

Product Quality Review: Overview and Feedback from Inspection

Product Quality Review: Overview and Feedback from Inspection Product Quality Review: Overview and Feedback from Inspection GMP/Market Compliance Information Day October 23 rd 2008 Lorraine Nolan Acting Inspection Manager IMB Slide 1 Scope of Presentation Overview

More information

Good manufacturing practices

Good manufacturing practices ORIGINAL PAPER 1AR-10 ISBT Science Series (2009) 4, 6 10 Journal compilation 2009 International Society of Blood Transfusion Good manufacturing practices Blackwell Publishing Ltd A. Ahmed Quality Manager,

More information

QUALITY quality standard that the data are credible and the rights, safety, integrity and confidentiality of the subjects are protected HOW???

QUALITY quality standard that the data are credible and the rights, safety, integrity and confidentiality of the subjects are protected HOW??? L.Massad GCP an International Ethical and Scientific quality standard by which clinical trials are designed, implemented and reported so that there is public assurance that the data are credible and the

More information

OECD Working Group on Good Laboratory Practice. Template for submission of comments on draft GLP Guidance Documents. Instructions for Use

OECD Working Group on Good Laboratory Practice. Template for submission of comments on draft GLP Guidance Documents. Instructions for Use OECD Working Group on Good Laboratory Practice Template for submission of comments on draft GLP Guidance Documents Instructions for Use 1. First, please complete the table below giving the full name of

More information

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT WHITE PAPER PRESENTED BY PREMIER RESEARCH Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT Quality Agreements are an effective bridge to a successful future for companies

More information

Harmonized Quality Requirements for Biotech Investigational Medicinal Products - A Regulator's View

Harmonized Quality Requirements for Biotech Investigational Medicinal Products - A Regulator's View Harmonized Quality Requirements for Biotech Investigational Medicinal Products - A Regulator's View Brigitte Brake Pharmaceutical Biotechnology BfArM, Bonn Evaluation Criteria National vs. EU Clinical

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q8, Q9, and Q10 Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics

More information

Comments from: 1. General comments. International Plasma Fractionation Association (IPFA) Our ref. IP

Comments from: 1. General comments. International Plasma Fractionation Association (IPFA) Our ref. IP Submission of comments on Commission proposal for Good Manufacturing Practice for Advanced Therapy Medicinal Products Comments from: Name of organisation or individual International

More information

References Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11.

References Concept. Principle. EU Annex 11 US FDA , (g), (i), 11 Orlando Lopez 2/15/11. Old Annex 11. References Concept Principle a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which

More information

DOWNLOAD PDF FINANCIAL AND QUALITY ASSURANCE REPORTING

DOWNLOAD PDF FINANCIAL AND QUALITY ASSURANCE REPORTING Chapter 1 : Financial Reporting & Assurance Services BT CPA Financial Reporting & Assurance Financial Insights to Fuel Business Growth Whether your business is expanding into a new market, preparing for

More information

GMPs: Distribution Centers

GMPs: Distribution Centers SkillsPlus International Inc. The On-Site Series GMPs: Distribution Centers Learn to apply the GMP regulations as they relate to distribution center operations! FDA Past, Present, and Future and opener

More information

QSIT INSPECTIONI HANDBOOK

QSIT INSPECTIONI HANDBOOK Management Controls Design Controls CAPA P&PC Sampling Plans FOOD AND DRUG ADMINISTRATION QSIT INSPECTIONI HANDBOOK October 1998 Draft 1 Table of Contents Introduction 2 Performing Subsystem Inspections

More information

SESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt

SESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt Validation Services SESSION 14 Documentation Requirements and Management for Validation 30 March 2017 Frits Vogt fritsvogt@valserv.nl Content Documentation Requirements and Management for Validation I.

More information

Challenges in Commercialization of Autologous Cell Therapy Products. Bryan Silvey & Kanti Thirumoorthy Kite Quality

Challenges in Commercialization of Autologous Cell Therapy Products. Bryan Silvey & Kanti Thirumoorthy Kite Quality Challenges in Commercialization of Autologous Cell Therapy Products Bryan Silvey & Kanti Thirumoorthy Kite Quality Aspects Unique to Autologous Cell Therapy: Product Challenges Complex starting material

More information

Achieves International Standards

Achieves International Standards Rising to Excellence How a China CRO Achieves International Standards Helen Yin, VP & GM Tigermed-MacroStat Minzhi Liu, GM, MacroStat July 7 th, 2012 1 Outline Selecting excellent staff Training staff

More information

Regulatory. Supplier Qualification A Review

Regulatory. Supplier Qualification A Review Supplier Qualification A Review Abstract: It is a GMP requirement to certify the vendor to deliver high quality and safe medicines, and to prevent recalls, deaths, adverse events, and serious illness due

More information

Ensure Data Integrity Compliance Enterprise-Wide

Ensure Data Integrity Compliance Enterprise-Wide Ensure Data Integrity Compliance Enterprise-Wide PharmaQual 360 º Conference February 24, 2017 Chris Wubbolt QACV Consulting, LLC www.qacvconsulting.com 1 Objectives What is data integrity and the definition

More information

COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE

COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE www.gratanet.com Among other regulations aimed at the implementation of the Agreement

More information

Standard Operating Procedures

Standard Operating Procedures Auditing of a Technology Vendor Checklist This checklist is intended to be a guide to planning your next audit. The items here should be evaluated for completeness. It is crucial for both Quality and the

More information

OCTC 2012 CRO Selection

OCTC 2012 CRO Selection OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed

More information

Compliance with the GMP Standard in the International Level

Compliance with the GMP Standard in the International Level Compliance with the GMP Standard in the International Level 27 th August 2018 Chandrashekar Ranga Deputy Drugs Controller (India) CDSCO (HQ) 1 Outline Provisions under the Drugs and Cosmetics Act, 1940

More information

Key Elements of Quality Assurance in the Good Laboratory Practice (GLP) Environment

Key Elements of Quality Assurance in the Good Laboratory Practice (GLP) Environment Key Elements of Quality Assurance in the Good Laboratory Practice (GLP) Environment The principles of Good Laboratory Practice (GLP) define a set of rules and criteria for a quality system concerned with

More information

Preventing, Detecting, and Responding to Data Integrity Events. Background, Recent Findings, and Agency Expectations

Preventing, Detecting, and Responding to Data Integrity Events. Background, Recent Findings, and Agency Expectations Preventing, Detecting, and Responding to Data Integrity Events Background, Recent Findings, and Agency Expectations Paula Katz Office of Manufacturing Quality Director, Guidance and Policy Staff FDA/PQRI

More information

Good Clinical Practice Inspections Expectations for Compliance with Sponsor Responsibilities, Part II

Good Clinical Practice Inspections Expectations for Compliance with Sponsor Responsibilities, Part II Good Clinical Practice Inspections Expectations for Compliance with Sponsor Responsibilities, Part II IMB Clinical Trials Seminar, 19 th June 2012 Ms. Sinead Curran GCP/Pharmacovigilance Inspector 22/06/2012

More information

Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE

Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE This project has been funded in whole or in part with Federal funds from the Division of AIDS (DAIDS), National Institute

More information

GxP Auditing, Remediation, and Staff Augmentation

GxP Auditing, Remediation, and Staff Augmentation GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7

More information

ICH Quality Implementation Working Group POINTS TO CONSIDER

ICH Quality Implementation Working Group POINTS TO CONSIDER ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements

More information

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active

More information

Lessons from Pharmaceutical Laboratory related FDA Warning Letters

Lessons from Pharmaceutical Laboratory related FDA Warning Letters Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance

More information

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit. FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis

More information

Develop a Roadmap for the Implementation of a Global CSV Program. Eileen Cortes April 26, 2017

Develop a Roadmap for the Implementation of a Global CSV Program. Eileen Cortes April 26, 2017 Develop a Roadmap for the Implementation of a Global CSV Program Eileen Cortes April 26, 2017 Agenda CSV Regulation Principles CSV Lifecycle Approach CSV and Quality Management Governance Program and CSV

More information

WHO GMP for Pharmaceutical Products: Main Principles

WHO GMP for Pharmaceutical Products: Main Principles 제약업계의품질경영 : 원칙과필수요소 (Quality management in the medicines industry: philosophy and essential elements) 1 In the medicines industry at large, quality management is usually defined as the aspect of the management

More information

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION 1 Working document QAS/13.527/Rev.1 April 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS

More information

PAI Inspections, Observations and Data Integrity

PAI Inspections, Observations and Data Integrity PAI Inspections, Observations and Data Integrity Krishna Ghosh, Ph.D. Office of Pharmaceutical Quality Office of Process and Facilities Center for Drug Evaluation and Research November, 2017 20 November

More information

Risk-based Approach to Part 11 and GxP Compliance

Risk-based Approach to Part 11 and GxP Compliance Welcome to our E-Seminar: Risk-based Approach to Part 11 and GxP Compliance 1 Intro Common Discussion Q: Do I really need to do this? Possible Answers A: Of course! (QA) B: Who cares, I have work to do!

More information

ICH E6 Guideline R 2 優良臨床試驗指引修改及增編附錄

ICH E6 Guideline R 2 優良臨床試驗指引修改及增編附錄 ICH E6 Guideline R 2 優良臨床試驗指引修改及增編附錄 Mandy Liu 劉文婷 COQM/ Boehringer Ingelheim Taiwan Ltd Former Team leader GCP inspection team/ CDE Member of Expert Working Group of ICH E6 2016.11.23 Statement of the

More information

22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852

22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852 22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:

More information

Addressing the Paradigm Shift in Regulatory Inspections

Addressing the Paradigm Shift in Regulatory Inspections An Executive Summary Addressing the Paradigm Shift in Regulatory Inspections Understanding the paradigm shift in a regulatory audit and what it means from an electronic system perspective. Humera Khaja

More information

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9 Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This

More information

Data Integrity Compliance Project

Data Integrity Compliance Project Data Integrity Compliance Project RISK FACTORS FOR DI ISSUES Outsourcing Supply Chain Data Review Practices Increasing use of electronic systems Economic Stressors 2 Fully Integrated into QMS DATA INTEGRITY

More information

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR

More information

The long anticipated draft of the FDA s

The long anticipated draft of the FDA s This article provides an overview of the draft guidance, the key changes in relation to the 1987 guidance, and reviews its potential impact on the current industry approaches to science- and risk-based

More information